Want to see DYN full AI Analyst Report?
DYN Stock Chart & Stats
$26.34
$0.55(2.30%)
At close: 4:00 PM EDT
$26.34
$0.55(2.30%)
Day’s Range― - ―
52-Week Range$14.00 - $27.31
Previous CloseN/A
Volume5.07M
Average Volume (3M)3.69M
Market Cap
$2.84B
Enterprise Value$3.01B
Total Cash (Recent Filing)$898.48M
Total Debt (Recent Filing)$19.87M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Oct 29, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding186,746,430
10 Day Avg. Volume3,520,150
30 Day Avg. Volume3,688,662
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.81K
Enterprise Value/Ebitda-6.08
Forecast
1Y Price Target
$34.67Price Target Upside31.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressSustained functional and patient-reported improvements, alongside a favorable safety profile, strengthen evidence for the DM1 program and the FORCE platform. Continued Phase 3 development and expected topline data could support regulatory submissions and improve the company’s path toward a targeted therapy.
Regulatory AdvancementPriority Review and a defined FDA action date represent meaningful advancement toward commercialization for DYNE-251. If approved, the program could move Dyne from a purely development-stage model toward product revenue and establish an initial position in the Duchenne muscular dystrophy treatment market.
Low LeverageVery low leverage reduces balance-sheet debt risk and preserves greater financial flexibility than a heavily debt-funded development model. Sizable assets also support liquidity and runway, giving Dyne more capacity to advance clinical programs while limiting the immediate burden of principal and interest obligations.
Bears Say
Pre-Revenue LossesDyne has not yet demonstrated product economics because revenue remains absent while losses continue to widen. The company therefore depends on clinical and regulatory progress before commercialization can offset operating costs, leaving profitability highly contingent on successful development and launch execution.
Cash BurnDeeply negative operating and free cash flow shows that Dyne’s research and development model consumes substantial cash without internally generated funding. Persistent burn increases dependence on future financing or partnership proceeds and can constrain the pace and scale of investment across its pipeline.
Equity DilutionThe large equity raise extends funding capacity but increases the share base and dilutes existing holders. Reliance on equity financing also signals that advancing programs requires continued external capital while the company remains pre-revenue, potentially reducing per-share participation in future success.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $14.00 and its highest was $27.30 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $2.84B.
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Jul 29, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.749 by -$0.331.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -0.91.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 186,746,430 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.749. Following the earnings report the stock price went up 2.51%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Currently, no hedge funds are holding shares in DYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyne Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.67 (31.61% Upside)
$34.67 (31.61% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.02%
12-Months-Change
Fundamentals
Return on Equity
-64.30%
Trailing 12-Months
Asset Growth
36.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dyne Therapeutics
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
DYN Stock 12 Month Forecast
Average Price Target
$34.67
▲(31.61% Upside)
Technical Analysis
Sarepta Therapeutics
―
PTC Therapeutics
―
Wave Life Sciences
―
Solid Biosciences
―
Edgewise Therapeutics
―
Ownership Overview
2.74% Insiders
25.88% Mutual Funds
0.20% Other Institutional Investors
55.43% Public Companies and
Individual Investors